| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK 1, MKK1, 2.7.12.2, ERK activator kinase 1, MAPK/ERK kinase 1, MEK 1, MAP2K1, MEK1, PRKMK1 |
| Entrez GeneID | 5604 |
| WB Predicted band size | 43.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This MP2K1 antibody is generated from a mouse immunized with a recombinant protein between 1-393 amino acids from human MP2K1. |
+ +
以下是关于MP2K1(MEK1)抗体的3篇模拟参考文献示例，内容基于典型研究场景概括：
---
1. **文献名称**：*"Characterization of a novel monoclonal antibody targeting MEK1 for cancer signaling studies"*
**作者**：Smith J. et al.
**摘要**：该研究报道了一种特异性识别MEK1(MP2K1)的新型单克隆抗体的开发与验证。通过Western blot和免疫沉淀实验证明其高特异性，并用于检测乳腺癌细胞中MEK1的激活状态及其与ERK通路的关联。
2. **文献名称**：*"MEK1 phosphorylation dynamics in neuronal differentiation revealed by phospho-specific antibodies"*
**作者**：Chen L. et al.
**摘要**：研究利用针对MEK1磷酸化位点(Ser218/222)的抗体，通过免疫荧光和流式细胞术分析神经元分化过程中MEK1的活化时序，揭示了其与突触形成的关键关联。
3. **文献名称**：*"Comparative analysis of commercial MEK1 antibodies in colorectal cancer biomarker detection"*
**作者**：Gupta R. et al.
**摘要**：系统性评估了5种市售MP2K1抗体的灵敏度和特异性，发现抗体Clone X-100在组织微阵列中表现最优，可有效区分结直肠癌患者的MEK1过表达与预后不良的关系。
---
注：以上文献为示例性内容，实际引用需以真实出版物为准。建议通过PubMed或Google Scholar以“MEK1 antibody”或“MP2K1 antibody”为关键词检索最新文献。
The MP2K1 antibody targets mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1), a dual-specificity kinase in the MAPK/ERK signaling pathway. MEK1 plays a pivotal role in transmitting extracellular signals (e.g., growth factors, hormones) to intracellular effectors, regulating cell proliferation, differentiation, survival, and apoptosis. It directly phosphorylates and activates ERK1/2. which subsequently modulates transcription factors and other downstream targets. Dysregulation of MEK1 is implicated in cancers, autoimmune disorders, and developmental diseases, often due to mutations (e.g., BRAF-MEK-ERK pathway hyperactivation in melanoma) or overexpression.
MP2K1 antibodies are essential tools for studying MEK1 expression, activation status (e.g., phosphorylated forms), and interactions in disease models or drug development. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry. In therapeutic contexts, MEK1 inhibitors (e.g., trametinib) are FDA-approved for cancers, and MP2K1 antibodies help validate drug efficacy or resistance mechanisms. These antibodies are typically generated in hosts like rabbits or mice, with specificity validated via knockout controls. Research using MP2K1 antibodies continues to unravel MEK1's role in pathophysiology and its potential as a biomarker or therapeutic target.
×
